Circulating Biomarkers of Thyroid Cancer: An Appraisal
- Marta Codrich 1, Alessia Biasotto 1,2, Federica D'Aurizio 1,2
- Marta Codrich 1, Alessia Biasotto 1,2, Federica D'Aurizio 1,2
- 1Department of Medicine (DMED), University of Udine, 33100 Udine, Italy.
- 2Institute of Clinical Pathology, Academic Hospital "Santa Maria della Misericordia", Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy.
- 0Department of Medicine (DMED), University of Udine, 33100 Udine, Italy.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This review examines circulating biomarkers for thyroid cancer diagnosis and monitoring. It highlights the limitations of current markers and the need for new, advanced biomarkers for better clinical management.
Area Of Science
- Endocrinology
- Oncology
- Biomarker Discovery
Background
- Thyroid cancer is the most common endocrine malignancy.
- Prognosis is influenced by cancer type and stage at diagnosis.
- Current treatments include surgery, hormone therapy, radiation, targeted therapy, and chemotherapy.
Purpose Of The Study
- To critically analyze the benefits and limitations of routinely measured circulating biomarkers for thyroid cancer.
- To explore emerging circulating biomarkers for thyroid cancer diagnosis and monitoring.
- To identify the need for a new generation of circulating biomarkers in clinical management.
Main Methods
- Literature review of current data on thyroid cancer biomarkers.
- Analysis of genomic, transcriptomic, and proteomic technologies for biomarker development.
- Critical evaluation of the clinical utility of established and novel circulating biomarkers.
Main Results
- Routine circulating biomarkers have limitations in diagnosis and monitoring of thyroid cancer.
- Advances in omics technologies are enabling the development of novel tumor biomarkers.
- New circulating biomarkers show promise but face challenges in clinical application.
Conclusions
- There is a need to overcome the limitations of current circulating biomarkers for thyroid cancer.
- Further research is required to validate and implement novel circulating biomarkers.
- Identifying a new generation of circulating biomarkers is crucial for improved thyroid cancer management.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
01:20
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
01:18
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...

